Scilex Holding announced that the U.S. Patent and Trademark Office, PTO, has allowed numerous claims from U.S. patent application no. 17/562,229 and will issue a new patent containing those claims related to the treatment of acute pain”), to Scilex in late 2024, further strengthening the Company’s intellectual property position and coverage for its acute migraine treatment drug product, ELYXYB(R), a liquid, micro-encapsulation formulation of celecoxib. The Patent, titled “Methods of Treating Pain,” covers methods of treating acute pain.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCLX:
- Scilex signs distribution agreement for ZTlido for parts of Africa, Middle East
- Scilex Holding Company Enters into Master Distributor Agreement Among CH Trading Group and Devart Middle East for the Distribution of ZTlido® in Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa
- Scilex reports preliminary July product sales $4.3M-$5.3M vs $2.8M last year
- Scilex Holding Bolsters Board with Dr. Navani’s Appointment
- Scilex Holding Company Announces Publication of Its Inaugural Sustainability Report